Scheduling Radionuclide Therapy (20,22)
| Therapies might be performed as scheduled. However, each patient must be assessed individually by clinical team or MDT prior to scheduling | Therapy requiring cancellation or rescheduling –each patient must be assessed individually, followed by liaison with clinical team or MDT. Inform patient |
| 177Lu-DOTATATE peptide receptor radionuclide therapy for metastatic neuroendocrine tumors (consider marrow depletion after procedure) | 131I therapy for thyroid cancer (follow thyroid cancer management guide for various risk categories) |
| Selective internal 90Y radioembolization therapy for hepatocellular carcinoma or liver metastases | 131I therapy for benign thyroid disease (most treatments can be postponed; give consideration to patients who cannot tolerate antithyroid medication) |
| 131I-metaiodobenzylguanidine therapy for metastatic pheochromocytoma or paraganglioma | Radiosynovectomy for arthritis, hemophilia, and similar conditions |
| 177Lu-prostate-specific membrane antigen therapy for metastatic prostate cancer | |
| 225Ac-prostate-specific membrane antigen therapy for metastatic prostate cancer | |
| 223Ra therapy for prostate cancer with skeletal metastases (consider comorbidities) |
Referrals must be reviewed by nuclear medicine consultants or in multidisciplinary setting. These are examples based on consensus only, and responsibility lies with each institution or hospital to ensure its written policy adheres to that outlined by national public health guidance in its respective country and hospital.